Russia is the first country to complete early phase human trials for COVID-19 vaccine.
Elena Smolyarchuk, chief researcher for the Russian Center for Clinical Research on Medications at Sechenov University, told TASS newswire on Sunday that human early trials for the vaccine had been completed and those test patients will be discharged soon.
She said that the research has been completed and it proved that the vaccine is safe. The volunteers will be discharged today on July 15th up to July 20th.
Ass for information on when the vaccine will enter commercial production, is unknown. No data is being revealed yet.
The testing sample was done on a group of 20 and this is an indication that the vaccine is still in its early stages. Most vaccines are tested by up to 100 people.
Russia had allowed clinical trials of two forms of a potential coronavirus vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology.
The first one was carried out at the Burdenko Military Hospital. The other vaccine was given to test patients at the Sechenov First Moscow State Medical University.
After receiving the vaccine, volunteers were told to quarantine for 28 days.
Earlier, results of the human trials for COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus, but what the drug actually is was not discussed in the article.